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1. Introduction 
Since Spotts and Starrier first suggested that strepto- 
mycin exerts its antibiotic by inhibiting protein synthe- 
sis in sensitive bacteria [l] , the antibiotic has been 
shown to act on such ribosomes in vivo and in vitro 
[2-41. In vitro studies have shown that streptomycin 
combines with the 30s ribosomal subunit [5-lo] , 
We have now studied the distribution of dihydro- 
streptomycin taken up by ribosomes in vivo at different 
stages of growth inhibition. This is important because 
one cannot necessarily apply conclusions drawn from 
in vitro effects to in vivo mechanisms. 
This report present results which show for the first 
time that the combination in vivo of dihydrostrepto- 
mycin with 30s ribosomal subunits is proportional to 
inhibition of growth and protein synthesis [ 11,121. 
We have also studied the addition of dihydrostrep- 
tomycin to ribosomal preparations in vitro to find out 
which binding sites are accessible, and the relation of 
such in vitro binding to in vivo effects. We found no 
competition between antibiotic added to intact cells 
during growth and antibiotic added to cell-free extracts; 
in other words, dihydrostreptomycin could bind to 
30s ribosomes in vitro after in vivo treatment had 
produced complete inhibition of growth. 
2. Materials and methods 
2.1. Growth of culture 
Escherichia coli MRE 600 was grown aerobically 
in mineral salts medium with 0.4% (w/v) glucose and 
0.2% (w/v) casamino acids at 32°C [13,14]. Cultures 
were labelled with [14C]uracil (8.63 X 10m2 pCi/mg, 
North-Holland Publishing Company - Amsterdam 
15 /q/ml of culture) to a constant specific activity. 
For this we allowed 2 generations of growth [ 1.51. 
Growth was measured as absorbance at 500 nm and 
plotted as Logs [ 16,131. 
2.2. In vivo dihydrostreptomycin treatment 
[” Hldihydrostreptomycin (75 &i/mg, 15 pg/ml 
culture) was added to logarithmically growing cultures. 
This high specific activity is necessary because strepto- 
mycin is effective at only 1 or a few molecules per 
ribosome (2,9,10,17). 
At various times after addition of dihydrostrepto- 
mycin the degree of growth inhibition was determined 
in the manner previously described [ 13,181: portions 
of cultures were rapidly filtered, washed 3 times with 
the mineral salts medium containing double the PO:- 
concentration and 10 mM Mg2+, and resuspended in 
antibiotic-free medium. Further incubation then 
allowed determination of the inhibited growth rates. 
Determinations of intracellular dihydrostreptomy- 
tin were carried out on the remaining portions of 
cultures. These were harvested by rapidly cooling to . 
below 4”C, centrifuging and washing in medium enriched 
with PO:-and Mg2’ as above. Since it had been calcu- 
lated from studies on streptomycin uptake [ 181 that 
the minimum concentration to produce complete 
inhibition of growth is of the order of 0.1 pg/mg dry 
weight cells, we argued that a level of labelled anti- 
biotic below this figure, remaining with the cell pellet, 
would indicate insignificant adsorption to the cell 
surface. It was found that 3 washes of the harvested 
cultures under these conditions were sufficient to 
reduce the dihydrostreptomycin concentrations to 
below this figure. 
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Cells were broken by alumina grinding and extracted 
with 10 mM Tris-HCl buffer pH 7.3 containing 10 
mM Mg2’and 60 mM KCl. Alumina and unbroken 
cells were removed by centrifuging at 20 000 g for 
15 min. 
Parts of the crude extracts were centrifuged at 
139 000 g for 5 l/4 hr in a 10 X 10 aluminium angle- 
head rotor on an MSE 50 centrifuge in order to pellet 
all the ribosomes (M. Cannon - personal communi- 
cation). The 3 H and r4C counts and absorbance at 
260 nm were measured for the ribosomal pellet and 
supernatant fractions. 
Another part of the crude extract was subjected to 
centrifugation through a 15-30% (w/v) linear sucrose 
gradient in the same Tris MG KC1 buffer for 6 l/4 hr 
at 94 000 g in the 3 X 23 aluminium swing-out rotor 
on an MSE-65 centrifuge at 5°C. The gradients were 
fractionated and collected as 25 drop fractions in 
parallel sets of tubes; the middle 3 drops of each frac- 
tion were used for absorbance measurements at 260 
nm. After plotting the profiles of the absorbance at 
260 nm, the 22 drop tubes containing polysomes, 70s 
monomers, 50s and 30s subunits and the top fractions 
of the gradients were pooled separately. The 3 H and 
14C counts in each of these pooled fractions were 
then measured. For counting, 0.2 ml samples were 
taken, and 0.8 ml of water added. They were then 
counted in 10 mls of a scintillation fluid containing 
4 g PPO, 0.1 g dimethyl POPOP, 500 ml Triton 
X-l 00 and 1 litre Toluene. 
For controls, untreated exponentially growing 
cultures (labelled with [’ 4 C] uracil) were harvested and 
after alumina grinding [j H] dihydrostreptomycin 
(approx. 0.1 pg/mg dry weight harvested cells) was 
added during extraction with buffer. These extracts 
were then further treated as above. 
2.3. In vitro treatment after complete inhibition in vivo 
In order to investigate any interaction between 
streptomycin added in vitro and in vivo, exponentially 
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Fig.1. Distribution of intracellular [“Hldihydrostreptomycin between ribosomes and supernatant fractions as a function of growth 
inhibition. Logarithmically growing [ “C]uracil-labelled cultures, treated with [ ‘Hldihydrostreptomycin (15 fig/ml) for various 
periods, were divided into two portions. One of these, after removal of extracellular antibiotic, as described in Materials and meth- 
ods, was further incubated to determine the extent of growth inhibition at the termination of treatment. The other portion. har- 
vested, freed from extra-cellular and adsorbed dihydrostreptomycin, was used for preparation of cell-free extract, as described, and 
one portion of this centrifuged to divide into ribosomal pellet and supernatant fraction. For each culture the intracellular dihydro- 
streptomycin in the 2 fractions, estimated as 3H/‘4C c.p.m., is plotted against he extent of growth inhibition. a) Ribosomal pellet; 
b) supernatant fraction. 
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growing cultures were treated with [3H]dihydrostrepto- 
mycin, as above, until growth had completely ceased. 
They were then harvested, ground with alumina, and 
varying concentrations of [3H]dihydrostreptomycin (in 
the range of 0.1-2.0 pg per mg dry weight of cells 
harvested) were added to the crude extracts. These 
were then centrifuged through 15-30% (w/v) sucrose 
gradients as before and the 25 drop fractions collected 
and pooled for counting and ODxe measurements as 
above. 
For this series also, controls of untreated exponen- 
tially growing cultures (labelled with [14C]uracil) were 
harvested, and the crude extracts treated with [3 H] 
dihydrostreptomycin in the same way as for the in vivo 
treated cultures. 
[“H] dihydrostreptomycin (3 Ci/mmol) and [4C] 
uracil(60 mCi/mmol) were obtained from the Radio- 
chemical Centre, Amersham. Unlabelled dihydrostrep- 
tomycin sulphate was a standard preparation generously 
supplied by Messrs. Glaxo Ltd. and has a specific activity 
of 780 I.U. per mg base. All other reagents were reagent 
grade. 
3. Results 
Fig. 1. shows the distribution of [ 3 H] dihydrostrep- 
tomycin between total ribosomal pellet and the super- 
natant after centrifugation at 139 000 g. In the 
pellet the ratio of 3H (that is dihydrostreptomycin) 
to “C (that is, RNA) increases linearly with increasing 
inhibition of growth rate, as shown by the calculated 
regression line. The supernatant graph shows a fairly 
constant ratio of 3 H/r4 C counts until growth inhibi- 
tion has proceeded to about 60 percent, and then a 
rapidly increasing rise at the later stages of inhibition, 
similar to the increases in total intracellular strepto- 
mycin previously observed [ 181. 
Fig.2 shows the distribution of 13H] dlhydrostrepto- 
mycin between different ribosome fractions obtained 
from the sucrose gradients. The picture for the 30s 
ribosomal subunits parallels the picture for the total 
ribosomal pellet. This confirms that dihydrostrepto- 
mycin, during its in vivo action combines with the 
30s subunits [14,19]. 
The graph for the 50s subunits rises during the 
early stages of growth inhibition, but then plateaus at 
approx. 40% inhibition. Similarly: the graph represen- 
ting the [3 H ] dihydrostreptomycin on polysomes and 
708 monomers also shows that there is no straight 
line relationship between the 3 H/i 4 C ratio and per- 
cent inhibition of growth rate. 
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Fig.2. Distribution of intracellular [3H]dihydrostreptomycin 
between various ribosomal components, as a function of growth 
inhibition. Portions of the crude cell-free xtracts, obtained as 
in fig.1, were sedimented through a 15-30% (w/v) linear sucrose 
gradient, in Tris/mg/KCl buffer, as described in Materials and 
methods, and the intracellular antibiotic associated with the 
various ribosomal components, estimated as 3H/‘4C c.p.m. 
plotted against growth inhibition of cultures from which they 
were obtained. a) 30s ribosomal subunits; b) SOS ribosomal 
subunits; c) 70s ribosomes (0); and polysomes (a). 
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Fig.3. Binding of [3H] dihydrostreptomycin to 30s ribosomal 
subunits in vitro and in vivo. Crude extracts, obtained from 
cultures without dihydrostreptomycin treatment, or after 
treatment with [ 3 Hldihydrostreptomycin to complete growth 
inhibition, were further treated with various concentrations of 
[ 3H]dihydrostreptomycin after removal of alumina and unbro- 
ken cells. 30s ribosomal subunits were then isolated by sedi- 
mentation through 15-30% (w/v) linear sucrose gradients as 
described, and the tritium counts and mg of ribosomes deter- 
mined. From the specific activity of the [ “Hldihydrostrepto- 
mycin used, the molecules of DHS per 30s subunit were 
determined and plotted against pg dihydrostreptomycin added 
in vitro per mg of dry weight of culture harvested for each 
preparation. a) In vitro binding of [’ Hldihydrostreptomycin 
to 30s ribosomes in extracts obtained from cultures treated 
with [aH]dihydrostreptomycin to complete growth inhibition. 
b) Calculated in vitro binding of [ 3H]dihydrostreptomycin to 
in vivo-treated 30s ribosomes, by substracting the values after 
in vivo treatment only from those in 3a. c) In vitro binding of 
[“Hldihydrostreptomycin to 30s ribosomes in extracts from 
untreated control cultures. 
On the graph for the 30s subunits the 3 points 
from the control cultures, i.e. at 0 inhibition, are very 
high. In fact, this in vitro binding seems to be as high 
as in vivo binding at 100% inhibition. This would sug 
gest that in vitro binding differs from in vivo binding 
which is related to the antibiotic effect. The question 
at this stage was: ‘does the antibiotic, in fact, bind to 
the same sites on the 30s ribosomal subunits when 
added in vitro as it does during in vivo treatment? 
In order to investigate this we added [3 H] dihydro- 
streptomycin to crude extracts from cultures harvested 
after in vivo treatment with dihydrostreptomycin had 
produced 100% inhibition of growth. We compared 
the in vitro binding under these conditions with in 
vitro binding in similar extracts from control cultures. 
If competition for in vivo binding sites and those acces- 
sible to the antibiotic in vitro did occur, then the 
binding to 30s ribosomes present in cell-free extracts 
from in vivo treated cultures should be less than such 
in vitro binding to ribosomes from controls. 
Fig.3 shows the ratios of molecules [3 H] DHS 
bound per 30s subunit, plotted against the concentra- 
tions of [3H] dihydrostreptomycin added to cell-free 
extracts (on the basis of mg dry weight of cells from 
which the extracts were prepared). The graph in 3a 
represents in vitro binding after in vivo inhibition; 3b 
is the calculated in vitro binding, obtained by subtrac- 
ting the in vivo binding (the points at 0 on the abscissa 
of graph 3a) from the results in fig.3a. Fig.3c repre- 
sents in vitro binding alone, i.e. to the controls (see 
Materials and methods). 
Comparing graphs 3b and 3c, it is quite clear that 
there is no competition for the sites accessible under 
these conditions in vitro and those occupied during in 
vivo treatment. Furthermore, this in vitro binding 
increases with increasing concentrations of DHS added 
to the crude extracts, to reach a plateau of approx. 2 
mol DHS per 30s ribosome. The number of molecules 
[3 H]DHS bound by 30s subunits during treatment in 
vivo, i.e. at the stage when growth had just ceased, 
was estimated in a number of experiments and found 
to be in the range of 0.45-0.8 molecules/30S ribosome. 
4. Discussion 
The results presented above fall into 2 sections. In 
the first we have studied the distribution of intracellu- 
lar dihydrostreptomycin as a function of growth inhi- 
bition. 
We have shown (fig.1) that, whilst the antibiotic 
associated with the ribosomal pellet increases linearly 
with increasing inhibition of growth, there is no such 
proportionality between the [3H]dihydrostreptomycin 
in the supernatant fraction and growth inhibition. This 
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would seem to confirm the idea that not all intracel- 
lular streptomycin is inhibitory at all stages [20] and 
some of the antibiotic in the latter fraction may corres- 
pond to the intracellular ‘pool streptomycin’ suggested 
on the basis of earlier work by Kogut et al. [18,19]. 
On comparing fig.2 with fig.1, it can be seen that 
the 30s subunits show the same picture as the total 
ribosomal pellet, that is the ribosome-bound strepto- 
mycin increases linearly with the extent of growth 
inhibition. Such a relationship is not seen with any 
other ribosomal component. This would seem to 
constitute the first real evidence for the generally 
accepted hypothesis that combination of dihydrostrep- 
tomycin (and streptomycin) with the 30s ribosomal 
subunits in vivo is directly involved in inhibition of 
growth and protein synthesis, i.e. its antibiotic action. 
Furthermore, the high levels of the 3 control points 
on the 30s graph of fig.2 (in vitro addition of dihydro- 
streptomycin to cell-free extracts) suggested that the 
accessibility of binding sites on the 30s subunits is 
different under in vivo and our in vitro conditions. We 
suggest herefore that the in vivo binding which is corre- 
lated with growth inhibition may be to specific inhibi- 
tory sites. 
The above observations led us to further investiga- 
tions, namely comparing in vitro binding of dihydro- 
streptomycin to 30s ribosomes in crude extracts after 
in viva inhibition, with such in vitro binding alone. 
The results show that the addition and binding of the 
antibiotic to 30s ribosomes in cell-free extracts is not 
prevented by previous in vivo treatment and binding 
to the ‘inhibitory’ sites. It would also appear, from our 
results, that such separate in vitro binding sites on 30s 
ribosomes are limited, i.e. approx. 2 per subunit. 
It is of interest, in this connection, that other wor- 
kers [9,10], studying in vitro binding of [3H]dihydro- 
streptomycin to isolated and purified 30s subunits (by 
equilibrium dialysis), have found approx. 1 molecule 
of DHS = 1 binding site per subunit. In our experiments, 
the values for in vivo binding at complete growth inhibi- 
tion were somewhat below one molecule DHS per 30s 
subunit. Thus, it would appear that not all 30s subu- 
nits in the cell need to have combined with the anti- 
biotic for growth to cease; perhaps not all 30s subunits 
are accessible to intracellular streptomycin [14,18,19]. 
Alternatively, the possibility that some of the 30s 
subunits may have lost their in vivo bound DHS during 
the isolation procedure (i.e. sucrose gradient centrifu- 
gation) cannot be ruled out. However, the in vitro 
binding of DHS to 30s ribosomes present in crude 
extracts, which we observed, could not be due merely 
to the presence of such unaffected 30s subunits in 
inhibited cultures, since two molecules DHS, hence 
2 binding sites were found per 20s ribosome. 
The apparent conflict between our results and the 
observations on in vitro binding to isolated 30s ribo- 
somes may be due to the different preparations and 
techniques used. Thus, additional binding sites or factors, 
present on 30s ribosomes in crude cell-free extracts, 
may be lost during isolation and purification, and/or 
conformational changes of the 30s subunits during the 
above procedures could alter the accessibility of binding 
sites to the antibiotic. Whether the one site per isolated 
30s subunit determined by Chang and Flaks [9] and 
Schreiner and Nierhaus [lo], is the same as our ‘in vivo 
binding site’ could be established by measuring the in 
vitro binding (or sites) by such isolated 30s ribosomes 
obtained from cultures which had been inhibited by 
streptomycin in vivo. Conformational changes of ribo- 
somal structure, caused by streptomycin treatment in 
vitro have been suggested by Sherman and Simpson [21]. 
Acknodedgement 
On of us (E.P) is in receipt of a Wellcome Foundation 
Studentship. 
References 
111 
VI 
[31 
141 
I51 
161 
171 
181 
191 
Spot&C. R. and Stanier, R. Y. (1961) Nature 192, 
633-637. 
Flaks, J. G., Cox, E. C. and White, J. R. (1962) Biochem. 
Biophys. Res. Commun. 7, 385-389. 
Luzzatto, L., Apirion, D. and Schlessinger, D. (1968) 
Proc. Natl. Acad. Sci. U.S. 60, 873-880. 
Kogut, M. (1969) J. Gen. Microbial. 57, 25. 
Cox. E. C., White, J. R. and Flaks, J. G. (1964) Proc. 
Natl. Acad. Sci. U.S. 54, 703-709. 
Davies, J. E. (1964) Proc. Natl. Acad. Sci. U.S. 51, 
659-664. 
Chang, F. N. and Flaks, J. G. (1970) Proc. Natl. Acad. 
Sci. U.S. 67, 1321-1328. 
Chang, F. N. and Flaks, J. G. (1972) Antimicrobial 
Agents & Chemoth. 2, 294-307. 
Chang, F. N. and Flaks, J. G. (1972) Antimicrobial 
Agents & Chemoth. 2, 308-319. 
41 
Volume 50, number 1 FEBSLETTERS January 1975 
[ 101 Schreiner, G. and Nierhaus, K. H. (1973) J. Mol. Biol. [16] Finney, D. J., Hazlewood, T. and Smith, M. J. (1955) J. 
81,71-82. Gen. Microbial. 12, 222. 
[ 111 Prizant, E. and Kogut, M. (1973) J. Gen. Microbial. 
75, (part 2) xi. 
[ 121’ Hipkiss, A. R. and Kogut, M. (1973) Transact. Biochem. 
sot. 1,594-596. 
[ 131 Kogut, M., Lightbown, J. W. and Isaacson, P. (1965) 
J. Gen. Microbial. 39, 155-164. 
[ 141 Kogut, M. and Harris, M. (1969) Eur. J. Biochem. 9, 
42-49. 
[17] Kaji, H. and Tanaka, Y. (1968) J. Mol. Biol. 32,221-230. 
[ 181 Kogut, M., Lightbown, J. W. and Isaacson, P. (1966) J. 
Gen. Microbial. 42, 333-344. 
[ 191 Kogut, M., Lightbown, J. W. and Isaacson, P. (1965) J. 
Gen. Microbial. 39, 165-183. 
[20] Hancock, R. (1962) J. Gen. Microbial. 28,503-516. 
[21] Sherman, M. I. and Simpson, M. U. (1969) Proc. Natl. 
Acad. Sci. U.S. 64, 1388-1395. 
[ 151 Kogut, M., Maltby, E. N. and Prizant, E. (1970) Biochem. 
J. 119,121-123. 
42 
